Doctor Abandons US Patent Application
By Solomon Times,
Solomon Times
| 04. 11. 2011
The patent application was launched by US based lawyers on behalf of Taiwanese scientist, Dr Ko Ying-Chin.
According to the US Patent Application Information Retrieval system, US based lawyers representing Taiwanese scientist, Dr Ko Ying-Chin, have since filed an express abandonment application on the first of this month for the patent application number.
NIPS says the express abandonment was subsequently processed by the US body on Monday this week and now the status of the US patent application is listed as "expressly abandoned.
Effectively, the patent application is now stopped.
This patent application entitled "Method and Kit for Assessing Risk of Gout and Hyperuricemia," uses samples from 192 Solomon Islanders, collected at the National Referral Hospital and two clinics in Guadalcanal Province during a research trip led by Dr Ko in September 2006.
Dr Ko and his colleagues only abandoned the patent application after NIPS, along with other non-governmental organizations in the Solomon Islands, began to publicly challenge it.
The basis of this challenge was Dr Ko's failure to obtain proper informed consent from the blood donors for such commercialization.
Related Articles
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...
By Charles Pulliam-Moore, The Verge | 03.21.2026
Like many people, director Valerie Veatch was intrigued when OpenAI first released its Sora text-to-video generative AI model to the public in 2024. Though she didn’t fully understand the technology, she was curious about what it could do, and she...
By Emily Mullin, Wired | 03.23.2026
As the Trump administration phases out the use of animal experimentation across the federal government, a biotech startup has a bold idea for an alternative to animal testing: nonsentient “organ sacks.”
Bay Area-based R3 Bio has been quietly pitching the...